GIMDx, Inc., a US subsidiary of Guangzhou Improve Medical Instruments Co., Ltd., announced today that the IMPROVACUTER® Gel & Clot Activator Tube and the IMPROSAFE® Blood Collection System received an annual FDA registration renewal allowing for the continued commercial expansion and distribution of these products in the US healthcare market. The IMPROVACUTER® Gel & Clot Activator Tube and the IMPROSAFE® Blood Collection System were originally registered with the FDA in 2010.

GIMDx states the IMPROVACUTER® Gel & Clot Activator Tube is a single use tube used to collect, transport, separate, and process venous blood specimens to obtain serum for clinical chemistry and immunology assays. One of its advantages over other brands in the market is having a superior serum separation method. This achieved by balancing the weights of the components to be separated. Additionally, the tube is designed to accommodate for actual local altitudes since the vacuum of these tubes compensates for external pressure. This is particularly important in low temperature environments that are common in the United States.

Furthermore, the IMPROSAFE® Blood Collection System is a venous blood drawing system that is a sterile, innocuous, convenient and safe medical device. Its tri-bevel needles are smooth and gentle, and the venipuncture is much less painful to the patient due a silicone coating around and inside the device.

Improve Medical’s blood collection systems and products are a complete solution for the pre-analytical, analytical and post- analytical phases of testing in clinical laboratories.